AR076083A1 - Anticuerpo monoclonal anti-rhesus d - Google Patents
Anticuerpo monoclonal anti-rhesus dInfo
- Publication number
- AR076083A1 AR076083A1 ARP100100663A ARP100100663A AR076083A1 AR 076083 A1 AR076083 A1 AR 076083A1 AR P100100663 A ARP100100663 A AR P100100663A AR P100100663 A ARP100100663 A AR P100100663A AR 076083 A1 AR076083 A1 AR 076083A1
- Authority
- AR
- Argentina
- Prior art keywords
- monoclonal antibody
- antibody
- rhesus
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Se posee un ácido nucleico que codifica la cadena pesada de un anticuerpo, un vector de expresion que lo comprende, una célula huésped, un método para producir el anticuerpo y una composicion farmacéutica. Reivindicacion 1: Un anticuerpo monoclonal anti-RhD, que es una inmunoglobulina IgG1 tetramérica compuesta de dos cadenas pesadas y dos cadenas livianas, la cadena pesada comprende la secuencia de aminoácido SEQ ID NO 2 y la cadena liviana comprende la secuencia de aminoácido SEQ ID NO 4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0951412A FR2942799B1 (fr) | 2009-03-06 | 2009-03-06 | Anticorps monoclonal anti-rhesus d |
Publications (1)
Publication Number | Publication Date |
---|---|
AR076083A1 true AR076083A1 (es) | 2011-05-18 |
Family
ID=40902101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100100663A AR076083A1 (es) | 2009-03-06 | 2010-03-05 | Anticuerpo monoclonal anti-rhesus d |
Country Status (16)
Country | Link |
---|---|
US (1) | US8404241B2 (es) |
EP (1) | EP2403529B1 (es) |
JP (1) | JP5474100B2 (es) |
KR (1) | KR101297343B1 (es) |
CN (1) | CN102341121B (es) |
AR (1) | AR076083A1 (es) |
AU (1) | AU2010219518B2 (es) |
BR (1) | BRPI1009241B1 (es) |
CA (1) | CA2753700C (es) |
DK (1) | DK2403529T3 (es) |
ES (1) | ES2533528T3 (es) |
FR (1) | FR2942799B1 (es) |
IL (1) | IL214755A (es) |
PL (1) | PL2403529T3 (es) |
TW (1) | TWI441921B (es) |
WO (1) | WO2010100383A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2702246T3 (es) * | 2012-03-26 | 2019-02-28 | Sanofi Sa | Formulaciones de agente de unión IgG4 estables |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
BR112015024926A2 (pt) * | 2013-04-16 | 2017-10-10 | Genentech Inc | composições, artigo de fabricação, métodos para tratar um paciente com câncer, para avaliar uma composição, para avaliar a atividade biológica, para produzir uma composição e para avaliar a fragmentação de uma composição e variante de pertuzumabe |
CN114409791B (zh) * | 2022-01-26 | 2023-01-24 | 南京医科大学 | 一种全人源抗人红细胞RhD全分子IgG及其制备方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
FR2807767B1 (fr) * | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
FR2861079B1 (fr) * | 2003-10-20 | 2007-09-28 | Lab Francais Du Fractionnement | Utilisation de cations metalliques divalents pour l'amelioration de l'activite fonctionnelle des anticorps. |
EP1771483A1 (en) * | 2004-07-20 | 2007-04-11 | Symphogen A/S | Anti-rhesus d recombinant polyclonal antibody and methods of manufacture |
UY29504A1 (es) * | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
CN101223448B (zh) * | 2005-05-20 | 2012-01-18 | 健泰科生物技术公司 | 来自自身免疫病受试者的生物学样品的预处理 |
PL1885399T3 (pl) * | 2005-05-26 | 2011-04-29 | Seattle Genetics Inc | Humanizowane przeciwciała anty-CD40 i sposoby ich stosowania |
RU2491094C2 (ru) * | 2007-03-30 | 2013-08-27 | Медиммун, Ллк | Препарат антитела |
-
2009
- 2009-03-06 FR FR0951412A patent/FR2942799B1/fr not_active Expired - Fee Related
-
2010
- 2010-03-05 EP EP10715299.3A patent/EP2403529B1/fr active Active
- 2010-03-05 PL PL10715299T patent/PL2403529T3/pl unknown
- 2010-03-05 CN CN201080010868.XA patent/CN102341121B/zh not_active Expired - Fee Related
- 2010-03-05 JP JP2011552493A patent/JP5474100B2/ja not_active Expired - Fee Related
- 2010-03-05 CA CA2753700A patent/CA2753700C/fr not_active Expired - Fee Related
- 2010-03-05 US US13/203,317 patent/US8404241B2/en active Active
- 2010-03-05 WO PCT/FR2010/050376 patent/WO2010100383A1/fr active Application Filing
- 2010-03-05 ES ES10715299.3T patent/ES2533528T3/es active Active
- 2010-03-05 KR KR1020117023546A patent/KR101297343B1/ko active IP Right Grant
- 2010-03-05 AU AU2010219518A patent/AU2010219518B2/en not_active Ceased
- 2010-03-05 AR ARP100100663A patent/AR076083A1/es not_active Application Discontinuation
- 2010-03-05 BR BRPI1009241-2A patent/BRPI1009241B1/pt not_active IP Right Cessation
- 2010-03-05 DK DK10715299T patent/DK2403529T3/en active
- 2010-03-05 TW TW099106514A patent/TWI441921B/zh not_active IP Right Cessation
-
2011
- 2011-08-18 IL IL214755A patent/IL214755A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20110140125A (ko) | 2011-12-30 |
ES2533528T3 (es) | 2015-04-10 |
AU2010219518B2 (en) | 2012-09-20 |
BRPI1009241B1 (pt) | 2019-11-05 |
IL214755A0 (en) | 2011-11-30 |
EP2403529A1 (fr) | 2012-01-11 |
US8404241B2 (en) | 2013-03-26 |
BRPI1009241A2 (pt) | 2016-10-11 |
AU2010219518A1 (en) | 2011-10-20 |
FR2942799B1 (fr) | 2011-02-25 |
CN102341121B (zh) | 2015-07-08 |
CN102341121A (zh) | 2012-02-01 |
TWI441921B (zh) | 2014-06-21 |
EP2403529B1 (fr) | 2014-12-31 |
DK2403529T3 (en) | 2015-04-13 |
IL214755A (en) | 2017-03-30 |
WO2010100383A1 (fr) | 2010-09-10 |
PL2403529T3 (pl) | 2015-07-31 |
FR2942799A1 (fr) | 2010-09-10 |
TW201043693A (en) | 2010-12-16 |
US20110311556A1 (en) | 2011-12-22 |
JP5474100B2 (ja) | 2014-04-16 |
CA2753700C (fr) | 2014-04-22 |
CA2753700A1 (fr) | 2010-09-10 |
KR101297343B1 (ko) | 2013-08-20 |
JP2012519478A (ja) | 2012-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20140979A1 (es) | Variantes de fc silenciosas de los anticuerpos anti-cd40 | |
CL2008002349A1 (es) | Molecula de anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que la comprende; método in vitro para suprimir células b que expresan cd37 en una población de células. | |
PE20141162A1 (es) | Anticuerpos anti-il-23 | |
ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
AR109355A2 (es) | Moléculas de unión al receptor ox40 humano | |
CY1119647T1 (el) | Αντισωματα προσδεσης αλβουμινης και τμηματα προσδεσης αυτων | |
AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
PE20171103A1 (es) | Anticuerpos heterodimericos que se unen a cd3 y cd38 | |
PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
CU20190087A7 (es) | Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1 | |
AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
PE20180042A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
ES2639026T3 (es) | Anticuerpos totalmente humanos específicos para CADM1 | |
PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
MX360741B (es) | Constructos de polipéptidos y sus usos. | |
SG10201807877TA (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
RU2014144143A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток | |
PE20131209A1 (es) | Anticuerpos anti-fap | |
EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
ES2421719T3 (es) | Antígeno de gliadina recombinante desamidada |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal | ||
FB | Suspension of granting procedure |